NeoGenomics (NEO) Q4 2024 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: Globe and Mail, The
Chief Financial Officer — Jeffrey Sherman Chief Commercial Officer — Warren Stone Chief Innovation Officer — Andrew Lukowiak Chief Operations Officer — Melody Harris Head of Strategy and Transformation — Kareem Saad Medical Director — Nate Montgomery TAKEAWAYS Revenue -- $172 million, reflecting an 11% increase. Clinical Testing Volumes -- Grew 9%, supported by a 5% lift in revenue per test. Adjusted Gross Margin -- Improved to 48%, the highest in 20 quarters. NGS Revenue -- Increased 24% for the quarter and 34% for the year, now representing over 30% of total revenue. Adjusted EBITDA -- Rose 27% in the quarter to $12 million, marking six consecutive quarters of positive performance. Full-year 2024 Results -- Revenue of $661 million, up 12%; adjusted EBITDA of $40 million, improving over 1,000%. Cash and Marketable Securities -- Ended at $387 million, down 7% sequentially. Full-year 2025 Guidance -- Revenue projected at $735 million-$745 million (11%-13% g
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration [Yahoo! Finance]Yahoo! Finance
- NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura IntegrationBusiness Wire
- NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026Business Wire
- NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026Business Wire
- 3 of Wall Street's Favorite Stocks We Think Twice About [Yahoo! Finance]Yahoo! Finance
NEO
Earnings
- 2/17/26 - Beat
NEO
Sec Filings
- 4/6/26 - Form DEFA14A
- 4/6/26 - Form ARS
- 4/6/26 - Form DEF
- NEO's page on the SEC website